Anzeige
Mehr »
Samstag, 04.10.2025 - Börsentäglich über 12.000 News
Golden Cross macht sich bereit: 1.350 Goldabbaustellen, 55 Ladder-Ziele und ein historischer Volltreffer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EN5G | ISIN: SE0020388577 | Ticker-Symbol: J8P
Frankfurt
03.10.25 | 08:21
1,582 Euro
+0,51 % +0,008
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CINCLUS PHARMA HOLDING AB Chart 1 Jahr
5-Tage-Chart
CINCLUS PHARMA HOLDING AB 5-Tage-Chart

Aktuelle News zur CINCLUS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.09.Cinclus Pharma Holding AB: Cinclus Pharma announces screening of first patient in HEEALING 1 Phase III trial evaluating linaprazan glurate for the treatment of erosive GERD109Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for acid-related diseases, today announced the screening of the first patient with...
► Artikel lesen
29.08.Cinclus Pharma Holding AB: Cinclus Pharma to initiate HEEALING 1 Phase III study of linaprazan glurate in patients with Erosive Gastroesophageal Reflux Disease (GERD)367Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company developing the next generation of treatments for acid-related diseases, today announced the initiation of its Phase III HEEALING...
► Artikel lesen
20.08.Cinclus Pharma Holding AB: Interim report January-June 2025 - Strengthened position for future value creation146"Our recently announced partnership with Zentiva k.s. for commercialization and manufacturing in Europe is a strong validation of both our product and strategic direction. This collaboration lays the...
► Artikel lesen
16.06.Cinclus Pharma Holding AB: Cinclus Pharma secures EMA and FDA pediatric study waivers for linaprazan glurate in H. pylori infection151Cinclus Pharma AB (publ), a clinical-stage pharmaceutical company developing next generation treatments for acid-related diseases, today announced that the European Medicines Agency (EMA) and the US...
► Artikel lesen
20.05.Cinclus Pharma Holding AB: Interim report January-March 2025212"In parallel with the preparations for the Phase III study, we are strengthening our presence and visibility in academia and the medical profession and intensifying the work for an upcoming commercialization....
► Artikel lesen
20.02.Cinclus Pharma Holding AB: Year-end report January - December 2024157"In many of the countries and regions where first-generation PCABs are launched, these are gradually taking over the market from the proton pump inhibitors (PPIs). Our ambition is to develop a unique...
► Artikel lesen
CINCLUS PHARMA Aktie jetzt für 0€ handeln
14.11.24Cinclus Pharma Holding AB: Interim Report January - September 2024173"The need for new alternatives to PPIs is evident as PCABs are making great progress worldwide," said Christer Ahlberg, CEO of Cinclus Pharma. Financial Summary, July - September 2024Net sales amounted...
► Artikel lesen
7 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1